 visitant ::
identificació
|
|||||||||||||||
|
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español | |||||||||
| Pàgina inicial > Articles > Articles publicats > Bruton tyrosine kinase covalent inhibition shapes the immune microenvironment in chronic lymphocytic leukemia |
(Universitat Autònoma de Barcelona) (Universitat Autònoma de Barcelona) (Vall d'Hebron Institut d'Oncologia) (Universitat Autònoma de Barcelona) (Barcelona Institute of Science and Technology (BIST)) (Vall d'Hebron Institut d'Oncologia) (Universitat Autònoma de Barcelona) (Universitat Autònoma de Barcelona) (Institut de Ciència i Tecnologia de Barcelona) (Vall d'Hebron Institut d'Oncologia) (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) (Hospital Universitario de Salamanca) (Hospital Clínic Universitari (València)) (Hospital Universitari i Politècnic La Fe (València)) (Universitat Autònoma de Barcelona) (Vall d'Hebron Institut d'Oncologia) (Vall d'Hebron Institut d'Oncologia) (Universitat Autònoma de Barcelona)
| Data: | 2025 |
| Resum: | Continuous treatment with ibrutinib not only exerts tumor control but also enhances T-cell function in patients with chronic lymphocytic leukemia (CLL). We conducted longitudinal multi-omics analyses in samples from CLL patients receiving ibrutinib upfront to identify potential adaptive mechanisms to Bruton tyrosine kinase (BTK) inhibition during the first 12 months of continuous therapy. We found that ibrutinib induced a decrease in the expression of exhaustion markers and the proportion of regulatory T cells and T-follicular helper cells normalized to levels observed in healthy donors. Functionally, the expression of genes related to activation, proliferation, differentiation, and metabolism were downregulated in T cells; after in vitro stimulation, proliferation capacity was only slightly modified by ibrutinib treatment, while cytokine production was increased. In CLL cells, we observed a downregulation of immunosuppression, adhesion, and migration proteins. Adaptation at molecular level, characterized by an increase in cancer cell fraction of CLL cells with mutated driver genes, was observed in around half of the patients and was associated with retained migrative capacity towards CXCL12/CXCR4 axis. Interestingly, BTK C481S mutations were detected as early as after 6 months of treatment, particularly enriched in subsets of malignant cells retaining migrative capacity. These CLL cells with potential migrative capacity under ibrutinib also exhibited a distinct transcriptomic profile including upregulation of mTOR-AKT and MYC pathways. We identified the high expression of TMBIM6 as a potential novel independent poor prognostic factor. Of note, BIA, a TMBIM6 antagonist, induced CLL cell apoptosis and synergized with ibrutinib. In summary, our comprehensive multi-omics analysis of CLL patients undergoing ibrutinib therapy has unveiled early immunomodulatory effects on T cells and adaptative mechanisms in CLL cells. These findings can contribute to the identification of resistance mechanisms and the discovery of novel therapeutic targets. |
| Ajuts: | Instituto de Salud Carlos III PI21/01190 Instituto de Salud Carlos III PI20/01274 Instituto de Salud Carlos III PI22/01204 Fundació la Marató de TV3 201905/30/31 Generalitat de Catalunya 2022FIB00092 |
| Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.  |
| Llengua: | Anglès |
| Document: | Article ; recerca ; Versió publicada |
| Publicat a: | Haematologica, Vol. 110 (march 2025) , p. 1758-1773, ISSN 1592-8721 |
